What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 42357/0177.


Rasagiline 1 mg tablets

Package leaflet: Information for the user

Rasagiline 1 mg tablets

Rasagiline

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Rasagiline is and what it is used for
2. What you need to know before you take Rasagiline
3. How to take Rasagiline
4. Possible side effects
5. How to store Rasagiline
6. Contents of the pack and other information

1. What Rasagiline is and what it is used for

Rasagiline is used for the treatment of Parkinson's disease. It can be used together with or without Levodopa (another medicine that is used to treat Parkinson's disease).

With Parkinson's disease, there is a loss of cells that produce dopamine in the brain. Dopamine is a chemical in the brain involved in movement control. Rasagiline helps to increase and sustain levels of dopamine in the brain.

2. What you need to know before you take Rasagiline

Do not take Rasagiline

  • if you are allergic (hypersensitive) to Rasagiline or any of the other ingredients of this medicine (listed in section 6)
  • if you have severe liver problems

Do not take the following medicines while taking Rasagiline:

  • monoamine oxidase (MAO) inhibitors (e.g. for treatment of depression or Parkinson's disease, or used for any other indication), including medicinal and natural products without prescription e.g. St. John's Wort.
  • pethidine (a strong pain killer).

You must wait at least 14 days after stopping Rasagiline treatment and starting treatment with MAO inhibitors or pethidine.

Warnings and precautions

Talk to your doctor before taking Rasagiline.

Take special care with Rasagiline

  • if you have mild to moderate liver problems
  • you should speak with your doctor about any suspicious skin changes

Children

Rasagiline is not recommended for use under the age of 18.

Other medicines and Rasagiline

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without prescription or if you are smoking or intend to stop smoking.

Ask your doctor for advice before taking any of the following medicines together with Rasagiline:

  • Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants)
  • the antibiotic ciprofloxacin used against infections
  • the cough suppressant dextromethorphan
  • sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine

The use of Rasagiline together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.

If you are starting treatment with Rasagiline, you should wait at least 5 weeks after stopping fluoxetine treatment.

If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping Rasagiline treatment.

Tell your doctor if you or your family/carer notices that you are developing unusual behaviours where you cannot resist the impulse, urges or cravings to carry out certain harmful or detrimental activities to yourself or others. These are called impulse control disorders. In patients taking Rasagiline and/or other medications used to treat Parkinson's disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed. Your doctor may need to adjust or stop your dose.

Rasagiline with food and drink

Rasagiline may be taken with or without food.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

No studies on the effects on the ability to drive and use machines have been performed. Ask your doctor for advice prior to driving or using machines.

3. How to take Rasagiline

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is 1 tablet of 1 mg taken by mouth once daily. Rasagiline may be taken with or without food.

If you take more Rasagiline than you should

If you think that you may have taken too many Rasagiline tablets, contact your doctor or pharmacist immediately. Take the Rasagiline carton box with you to show the doctor or pharmacist.

If you forget to take Rasagiline

Do not take a double dose to make up for a forgotten dose. Take the next dose normally, when it is lime to take it.

If you stop taking Rasagiline

Do not stop taking Rasagiline without first talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been reported in placebo controlled clinical trials:

The frequency of possible side effects listed below is defined using the following convention:

  • Very common (may affect more than 1 in 10 people)
  • Common (may affect up to 1 in 10 people)
  • Uncommon (may affect up to 1 in 100 people)
  • Rare (may affect up to 1 in 1,000 people)
  • Very rare (may affect up to 1 in 10,000 people)
  • Not known (frequency cannot be estimated from the available data)

Very common

abnormal movements (dyskinesia)

  • headache

Common

  • abdominal pain
  • fall
  • allergy
  • fever
  • flu (influenza)
  • general feeling of being unwell (malaise)
  • neck pain
  • chest pain (angina pectoris)
  • low blood pressure when rising to a standing position with symptoms like dizziness/light-headedness (orthostatic hypotension)
  • decreased appetite
  • constipation
  • dry mouth
  • nausea and vomiting
  • flatulence
  • abnormal results of blood tests (leucopenia)
  • joint pain (arthralgia)
  • musculoskeletal pain
  • joint inflammation (arthritis)
  • numbness and muscle weakness of the hand (carpal tunnel syndrome)
  • decreased weight
  • abnormal dreams
  • difficulty in muscular coordination (balance disorder)
  • depression
  • dizziness (vertigo)
  • prolonged muscle contractions (dystonia)
  • runny nose (rhinitis)
  • irritation of the skin (dermatitis)
  • rash
  • bloodshot eyes (conjunctivitis)
  • urinary urgency

Uncommon

  • stroke (cerebrovascular accident)
  • heart attack (myocardial infarction)
  • blistering rash (vesiculobullous rash)

In addition, skin cancer was reported in around 1 % of patients in the placebo controlled clinical trials. Nevertheless, scientific evidence suggests that Parkinson's disease, and not any medicine in particular, is associated with a higher risk of skin cancer (not exclusively melanoma). You should speak with your doctor about any suspicious skin changes.

Parkinson's disease is associated with symptoms of hallucinations and confusion.

In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with rasagiline.

There have been cases of patients who, while taking one more medications for the treatment of Parkinson's disease, were unable to resist the impulse, drive or temptation to perform an action that could be harmful to themselves or others. These are called impulse control disorders. In patients taking rasagiline and/or other medications used to treat Parkinson's disease, the following have been observed:

  • Obsessive thoughts or impulsive behaviour
  • Strong impulse to gamble excessively despite serious personal or family consequences
  • Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive
  • Uncontrollable excessive shopping or spending

Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the

Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Rasagiline

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or blister. The expiry date refers to the last day of that month.

Do not store above 25°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Rasagiline contains

  • The active substance is rasagiline. Each tablet contains 1 mg rasagiline (as tartrate)
  • The other ingredients are microcrystalline cellulose, tartric acid, maize starch, pregelatinized starch, talc, stearic acid

What Rasagiline looks like and contents of the pack

Rasagiline tablets are presented as white to off-white, oblong (approximately 11.5 mm x 6 mm) bioconvex tablets, debossed with "R9SE" on one side and '1' on the other side.

The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Amneal Pharma Europe Limited
70 Sir John Rogerson's Quay
Dublin 2
Ireland

Manufacturer:

Synthon Hispania SL
C/ Castelló no1
Pol. Las Salinas
Sant Boi de Llobregat
Barcelona 08830
Spain

Synthon s.r.o.
Brnenská 32/cp. 597
Blansko 678 01
Czech Republic

This leaflet was last revised in October 2015

372820-01

Laetus 1141